These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 29571923)

  • 1. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector.
    Bowles DE; McPhee SW; Li C; Gray SJ; Samulski JJ; Camp AS; Li J; Wang B; Monahan PE; Rabinowitz JE; Grieger JC; Govindasamy L; Agbandje-McKenna M; Xiao X; Samulski RJ
    Mol Ther; 2012 Feb; 20(2):443-55. PubMed ID: 22068425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of Adeno-Associated Virus-9-Neutralizing Antibody in Chinese Patients with Duchenne Muscular Dystrophy.
    Wei C; Li D; Zhang M; Zhao Y; Liu Y; Fan Y; Wang L; Liu J; Chang X; Jiang Y; Xiong H
    Hum Gene Ther; 2024 Jan; 35(1-2):26-35. PubMed ID: 38084965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of AAV1 neutralizing antibodies and consequences for a clinical trial of gene transfer for advanced heart failure.
    Greenberg B; Butler J; Felker GM; Ponikowski P; Voors AA; Pogoda JM; Provost R; Guerrero J; Hajjar RJ; Zsebo KM
    Gene Ther; 2016 Mar; 23(3):313-9. PubMed ID: 26699914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intramuscular administration of AAV overcomes pre-existing neutralizing antibodies in rhesus macaques.
    Greig JA; Calcedo R; Grant RL; Peng H; Medina-Jaszek CA; Ahonkhai O; Qin Q; Roy S; Tretiakova AP; Wilson JM
    Vaccine; 2016 Dec; 34(50):6323-6329. PubMed ID: 27817961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutralizing Antibodies Against Adeno-Associated Viral Capsids in Patients with mut Methylmalonic Acidemia.
    Harrington EA; Sloan JL; Manoli I; Chandler RJ; Schneider M; McGuire PJ; Calcedo R; Wilson JM; Venditti CP
    Hum Gene Ther; 2016 May; 27(5):345-53. PubMed ID: 26790480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humoral immunity to AAV-6, 8, and 9 in normal and dystrophic dogs.
    Shin JH; Yue Y; Smith B; Duan D
    Hum Gene Ther; 2012 Mar; 23(3):287-94. PubMed ID: 22040468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
    Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-Related Seroprevalence of Antibodies Against AAV-LK03 in a UK Population Cohort.
    Perocheau DP; Cunningham S; Lee J; Antinao Diaz J; Waddington SN; Gilmour K; Eaglestone S; Lisowski L; Thrasher AJ; Alexander IE; Gissen P; Baruteau J
    Hum Gene Ther; 2019 Jan; 30(1):79-87. PubMed ID: 30027761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy.
    van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V
    Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of neutralizing antibodies against AAV serotype 1 in healthy subjects in China: implications for gene therapy and vaccines using AAV1 vector.
    Liu Q; Huang W; Zhao C; Zhang L; Meng S; Gao D; Wang Y
    J Med Virol; 2013 Sep; 85(9):1550-6. PubMed ID: 23852678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus antibody profiles in newborns, children, and adolescents.
    Calcedo R; Morizono H; Wang L; McCarter R; He J; Jones D; Batshaw ML; Wilson JM
    Clin Vaccine Immunol; 2011 Sep; 18(9):1586-8. PubMed ID: 21775517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Serum rAAV Serotype-Specific Antibodies in Patients with Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, Inclusion Body Myositis, or GNE Myopathy.
    Zygmunt DA; Crowe KE; Flanigan KM; Martin PT
    Hum Gene Ther; 2017 Sep; 28(9):737-746. PubMed ID: 28042944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.